This observation might imply different underlying anti-tumor mechanisms for AN3025 and anti-PD-1 antibody, suggesting a combination treatment of AN3025 and anti-PD-1 antibody might achieve better anti-tumor efficacy. The gene discussed is PDCD1; the disease is neoplasm.